shopping cart Your cart is empty
  • Home
  • Healthcare
  • Neurological Diseases Treatment Market By Drug Type (Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedative, Analgesic...

Neurological Diseases Treatment Market By Drug Type (Anticholinergic, Antiepileptic, Antipsychotic, Hypnotic & Sedative, Analgesics, Antihypertensive, Anticoagulants), By Disease (Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Published By: Brisk Insights | Published On: Jun 1, 2022

 

The report titled “Neurological Diseases Treatment Market- Growth, Future Prospects, and Competitive Analysis, 2017 – 2025” offers strategic insights into the overall neurological diseases treatment market along with the market size and estimates for the duration 2015 to 2025. The said research study cover in-depth analysis of neurological treatment market segments based on type of drugs, diseases and different geographies further segmented by countries.

 

For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of drug type into anticholinergic, antiepileptic, antipsychotic, hypnotic & sedative, analgesics, antihypertensive, anticoagulants, and others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

 

For the purpose of this study, the global neurological diseases treatment market is segmented on the basis of diseases type into epilepsy, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, cerebrovascular disease, and others. Market size estimates and forecast for these segments for the period 2015 to 2025 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2017 to 2025, considering 2016 as the base year.

 

The geographical segmentation of neurological diseases market comprised regions such as North America, Europe, Asia-Pacific, Latin America & Middle East and Africa. Each geographical region is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, Mexico, Saudi Arabia, South Africa, and other countries. Market size and forecast for these segments during 2015 to 2025 and their CAGRs for the period 2017 to 2025 are provided in this report.

 

The neurological diseases treatment market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc among others.

 

Based on the type of drug, the global neurological diseases treatment market is segmented as follows:

 

  • Anticholinergic
  • Antiepileptic
  • Antipsychotic
  • Hypnotic & Sedative
  • Analgesics
  • Antihypertensive
  • Anticoagulants
  • Others

 

In 2016, anticholinergic and antiepileptic drugs accounted for around 42% of the market share together. The key driving factors assisting the growth of these two segments are rising prevalence of neurological diseases, incessant development in diagnostic technology, and rising awareness associated with early disease diagnosis through awareness campaigns carried out by governmental or non-governmental organizations. However, market entry of efficient drugs in the near future due to presence of strong drug pipeline is expected to change the market share of traditional drug treatments and further boost the overall growth of this market. SER – 214 (Rotigotine) proprietary clinical candidate currently present in phase2 of clinical trials belongs to Serina Therapeutics, Inc. The research study suggests that SER – 214 is delivered subcutaneously, provides continuous dopaminergic stimulation, and steady-state levels of plasma rotigotine that cannot be achieved by any other approach.

 

Based on the type of disease, the global neurological diseases treatment market is segmented as follows:

 

  • Epilepsy
  • Alzheimer’s disease
  • Parkinson’s disease
  • Multiple Sclerosis
  • Cerebrovascular disease
  • Others

 

In year 2016, epilepsy, Alzheimer’s and Parkinson’s disease accounted for more than 50% of the market share together due to rising prevalence of these diseases, introduction of novel diagnostic technology for neurological diseases, and rising awareness programs organized by governmental and non-governmental organizations. According to World Health Organization (WHO), approximately 50 million people worldwide have epilepsy, making it one of the most common neurological diseases globally and nearly 80% of the people with epilepsy live in low- and middle-income countries. Rising research and development activities in the field of neurology has been the key driver of neurological diseases treatment market and is expected to fuel its growth throughout the forecast period 2017 – 2025.

 

For the purpose of this study, the global neurological diseases treatment market is categorized into:

 

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

 

In base year 2016, North America accounted for the largest share in global neurological diseases treatment market due to key driving factors such as rising prevalence of neurological diseases, rising awareness associated with early neurological disease diagnosis and treatment, supportive reimbursement policies, and incessant developments in the field of research and development. According to a research report, an estimated 5.4 million Americans have Alzheimer’s disease and today someone in America develops Alzheimer’s disease every 68 seconds. By 2050, there is expected to be one new case of Alzheimer’s disease every 33 seconds, or nearly a million new cases per year, and Alzheimer’s disease prevalence is projected to be 11 million to 16 million. During the forecast period 2017 – 2025, Asia Pacific was observed as the fastest growing region due to key driving factors such as increasing prevalence of neurological disorders, developing healthcare infrastructure, rising awareness associated with neurological diseases which is fueling the rate of diagnosis, and mounting accessibility of modern treatments in developing countries such as China, India, and Indonesia.

 

Chapter 1. Preface


1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

 

Chapter 2. Executive Summary


2.1. Global Neurological Diseases Treatment Market Portraiture
2.2. Global Neurological Diseases Treatment Market, By Drug Type, 2016 (US$ Mn)
2.3. Global Neurological Diseases Treatment Market, By Diseases Type, 2016 (US$ Mn)
2.4. Global Neurological Diseases Treatment Market, by Geography, 2016 Vs 2025 (Value %)

 

Chapter 3. Neurological Diseases Treatment Market: Market Dynamics and Future Outlook


3.1. Market Overview
3.2. Neurological Diseases: Epidemiology
3.3. Neurological Diseases Treatment: Future Trends
3.4. Drivers
3.5. Challenges
3.6. Opportunities
3.7. Attractive Investment Proposition, by Geography, 2016
3.8. Major Agreements, Partnerships and Collaborations
3.9. Competitive Landscape
3.9.1. Competitive Landscape, by Key Players, 2016



Chapter 4. Global Neurological Diseases Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)


4.1. Overview
4.1.1. Attractive Investment Proposition: Global Neurological Diseases Treatment Market, by Drug Type
4.2. Anticholinergic
4.3. Antiepileptic
4.4. Antipsychotic
4.5. Hypnotic & Sedative
4.6. Analgesics
4.7. Antihypertensive
4.8. Anticoagulants
4.9. Others

 

Chapter 5. Global Neurological Diseases Treatment Market: Pipeline Analysis


5.1. Overview
5.2. Phase III (Market estimations by 2025)
5.2.1. NRL-1 (Neurelis, Inc.)
5.2.2. YKP3089 (SK Life Science)
5.2.3. GWP42003-P (GW Research Ltd.)
5.2.4. ZX008 (Zogenix, Inc.)
5.2.5. RAD001 (Novartis AG)
5.2.6. E2007 (Eisai Co., Ltd.)
5.2.7. Elenbecestat (E2609) (Eisai Co., Ltd., Biogen)
5.2.8. ALZT-OP1 (AZTherapies, Inc.)
5.2.9. Aducanumab (BIIB037) (Biogen)
5.2.10. ITI-007 (Intra-Cellular Therapies, Inc.)
5.2.11. CAD106 (Novartis AG)
5.2.12. CNP520 (Novartis AG)
5.2.13. 18F-AV-1451 (Avid Radiopharmaceuticals)
5.2.14. AVP-786 (Avanir Pharmaceuticals)
5.2.15. JNJ-54861911 (Janssen Research & Development, LLC)
5.2.16. APL-130277 (Sunovion Pharmaceuticals, Inc.)
5.2.17. ABT-SLV187 (AbbVie, Inc.)
5.2.18. ND0612 (NeuroDerm Ltd.)
5.2.19. MD1003 (MedDay Pharmaceuticals SA)
5.2.20. ALKS 8700 (Alkermes, Inc.)
5.2.21. Gilenya (Sheffield Teaching Hospitals NHS Foundation Trust)
5.2.22. Avonex (Biocard)
5.2.23. Rivaroxaban (Xarelto, BAY59-7939) (Bayer & Janssen )
5.2.24. NA-1 (NoNO Inc.)
5.3. Phase II (Qualitative Information)
5.4. Phase I (Qualitative Information)
5.5. Preclinical Studies (Quantitative Information)

 

Chapter 6. Global Neurological Diseases Treatment Market, by Disease, 2015 – 2025 (US$ Mn)


6.1. Overview
6.2. Epilepsy
6.3. Alzheimer’s disease
6.4. Parkinson’s disease
6.5. Multiple Sclerosis
6.6. Cerebrovascular disease
6.7. Others

 

Chapter 7. Global Neurological Diseases Treatment Market, by Geography, 2015 – 2025 (US$ Mn)


7.1. Overview
7.2. North America Neurological Diseases Treatment Market Analysis, 2015 – 2025
7.2.1. North America Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
7.2.2. North America Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
7.2.3. North America Neurological Diseases Treatment Market, by Country, 2015 – 2025 (US$ Mn)
7.2.3.1. U.S.
7.2.3.2. Canada
7.3. Europe Neurological Diseases Treatment Market Analysis, 2015 – 2025
7.3.1. Europe Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
7.3.2. Europe Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
7.3.3. Europe Neurological Diseases Treatment Market, by Country, 2015 – 2025 (US$ Mn)
7.3.3.1. U.K.
7.3.3.2. Germany
7.3.3.3. France
7.3.3.4. Spain
7.3.3.5. Italy
7.3.3.6. Rest of Europe
7.4. Asia Pacific Neurological Diseases Treatment Market Analysis, 2015 – 2025
7.4.1. Asia Pacific Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
7.4.2. Asia Pacific Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
7.4.3. Asia Pacific Neurological Diseases Treatment Market, by Country, 2015 – 2025 (US$ Mn)
7.4.3.1. Japan
7.4.3.2. China
7.4.3.3. India
7.4.3.4. Rest of APAC
7.5. Latin America Neurological Diseases Treatment Market Analysis, 2015 – 2025
7.5.1. Latin America Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
7.5.2. Latin America Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
7.5.3. Latin America Neurological Diseases Treatment Market, by Country, 2015 – 2025 (US$ Mn)
7.5.3.1. Brazil
7.5.3.2. Mexico
7.5.3.3. Rest of Latin America
7.6. Middle East & Africa (MEA) Neurological Diseases Treatment Market Analysis, 2015 – 2025
7.6.1. MEA Neurological Diseases Treatment Market, by Drug Type, 2015 – 2025 (US$ Mn)
7.6.2. MEA Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
7.6.3. MEA Neurological Diseases Treatment Market, by Region, 2015 – 2025 (US$ Mn)
7.6.3.1. UAE
7.6.3.2. Saudi Arabia
7.6.3.3. South Africa
7.6.3.4. Rest of MEA

 

Chapter 8. Company Profiles


8.1. Novartis AG
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. GlaxoSmithKline plc
8.3. Merck & Co.
8.4. Bayer AG
8.5. AstraZeneca plc
8.6. Boehringer Ingelheim GmbH
8.7. Teva Pharmaceutical Industries Ltd.
8.8. F. Hoffmann-La Roche Ltd.
8.9. Neurelis, Inc.
8.10. SK Life Science
8.11. GW Research Ltd.
8.12. Zogenix, Inc.
8.13. Eisai Co., Ltd.
8.14. AZTherapies, Inc.
8.15. Biogen, Inc.
8.16. Intra-Cellular Therapies, Inc.
8.17. Avid Radiopharmaceuticals
8.18. Avanir Pharmaceuticals
8.19. Janssen Research & Development, LLC
8.20. Sunovion Pharmaceuticals, Inc.
8.21. AbbVie, Inc.
8.22. NeuroDerm Ltd.
8.23. MedDay Pharmaceuticals SA

TABLE 1 Global Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 2 Global Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 3 Global Neurological Diseases Treatment Market, By Geography, 2015 – 2025 (US$ Mn)
TABLE 4 North America Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 5 North America Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
TABLE 6 North America Neurological Diseases Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 8 Europe Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Neurological Diseases Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 10 Asia Pacific Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
TABLE 12 Asia Pacific Neurological Diseases Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 13 Latin America Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
TABLE 15 Latin America Neurological Diseases Treatment Market, By Country, 2015 – 2025 (US$ Mn)
TABLE 16 Middle East And Africa Neurological Diseases Treatment Market, By Drug Type, 2015 – 2025 (US$ Mn)
TABLE 17 Middle East And Africa Neurological Diseases Treatment Market, By Disease Type, 2015 – 2025 (US$ Mn)
TABLE 18 Middle East And Africa Neurological Diseases Treatment Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 19 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 20 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Merck & Co.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 Bayer AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Boehringer Ingelheim GmbH: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 F. Hoffmann-La Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Neurelis, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 SK Life Science: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 GW Research Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 30 Zogenix, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 31 Eisai Co., Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 32 AZTherapies, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 33 Biogen, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 34 Intra-Cellular Therapies, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 35 Avid Radiopharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 36 Avanir Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 37 Janssen Research & Development, LLC: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 38 Sunovion Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 39 AbbVie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 40 NeuroDerm Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 41 MedDay Pharmaceuticals SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

FIG. 1 Neurological Diseases Treatment: Market Segmentation
FIG. 2 Global Neurological Diseases Treatment Market Share, By Drug Type, 2016 (US$ Mn)
FIG. 3 Global Neurological Diseases Treatment Market Share, By Disease Type, 2016 (US$ Mn)
FIG. 4 Global Neurological Diseases Treatment Market, by Geography, 2016 Vs 2025 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography, 2016
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Anticholinergic Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 8 Global Antiepileptic Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 9 Global Antipsychotic Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 10 Global Hypnotic & Sedative Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 11 Global Analgesics Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 12 Global Antihypertensive Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 13 Global Anticoagulants Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 14 Global Other Drugs Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 15 Global Biophosphonates Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 16 Global NRL-1 Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 17 Global YKP3089 Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 18 Global GWP42003-P Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 19 Global ZX008 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 20 Global RAD001 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 21 Global E2007 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 22 Global Elenbecestat (E2609) Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 23 Global ALZT-OP1 Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 24 Global Aducanumab (BIIB037) Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 25 Global ITI-007 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 26 Global CAD106 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 27 Global CNP520 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 28 Global 18F-AV-1451 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 29 Global AVP-786 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 30 Global JNJ-54861911 Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 31 Global APL-130277 Market In Neurological Diseases Treatment, 2015 – 2025 (US$ Mn)
FIG. 32 Global ABT-SLV187 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 33 Global ND0612 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 34 Global MD1003 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 35 Global ALKS 8700 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 36 Global Gilenya Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 37 Global Avonex Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 38 Global Rivaroxaban (Xarelto, BAY59-7939) Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 39 Global NA-1 Market In Neurological Diseases Treatment (Forecast By 2025) (US$ Mn)
FIG. 40 Global Epilepsy Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 41 Global Alzheimer’s Disease Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 42 Global Parkinson’s Disease Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 43 Global Multiple Sclerosis Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 44 Global Cerebrovascular Disease Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 45 Global Other Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 46 U.S. Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 47 Canada Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 48 U.K. Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 49 Germany Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 50 France Neurological Diseases Treatment Market, 2015-2025 (US$ Mn)
FIG. 51 Spain Neurological Diseases Treatment Market, 2015-2025 (US$ Mn)
FIG. 52 Italy Neurological Diseases Treatment Market, 2015-2025 (US$ Mn)
FIG. 53 Rest Of Europe Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 54 Japan Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 55 China Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 56 India Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 57 Rest Of Asia Pacific Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 58 Brazil Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 59 Mexico Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 60 Rest Of Latin America Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 61 UAE Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 62 Saudi Arabia Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 63 South Africa Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)
FIG. 64 Rest Of Middle East And Africa Neurological Diseases Treatment Market, 2015 – 2025 (US$ Mn)

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)